<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02459353</url>
  </required_header>
  <id_info>
    <org_study_id>ISSDAPA0006</org_study_id>
    <nct_id>NCT02459353</nct_id>
  </id_info>
  <brief_title>Effect of Dapagliflozin on Glycemic Variability</brief_title>
  <acronym>DIVE</acronym>
  <official_title>Effect of Dapagliflozin on Glycemic Variability as an add-on Therapy in Subjects With Type 2 Diabetes Mellitus With in Inadequate Glycemic Control in Insulin: a Multicenter, Placebo-controlled, Double-blind, Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Catholic University of Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eulji General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kyung Hee University Hospital at Gangdong</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Catholic University of Korea</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dapagliflozin improves glycemic variability in subjects with type 2 diabetes mellitus when&#xD;
      added to insulin therapy. The primary objective of this study is to assess the effect of&#xD;
      dapagliflozin on glucose variability compared to placebo after 12 weeks of treatment in type&#xD;
      2 diabetic patients with inadequate glycemic control on insulin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a multicenter, randomized, double-blind, placebo-controlled phase 4 study to&#xD;
      evaluate whether treatment with dapagliflozin add-on to insulin reduces glucose variability&#xD;
      in type 2 Diabetes Mellitus. The study will recruit type 2 Diabetes Mellitus patients with&#xD;
      inadequate glucose control on insulin treatment with or without metformin or sulphonylurea.&#xD;
      It is estimated that 90 type 2 diabetic patients will be enrolled. After randomization, a&#xD;
      total 12 week treatment of dapagliflozin or matching placebo will be administered. Before and&#xD;
      after treatment, tests for efficacy and safety outcomes will be performed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2015</start_date>
  <completion_date type="Actual">May 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glycemic Variability (mean amplitude of glycemic excursion)</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>MAGE(mean amplitude of glycemic excursion)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Glycemic Variability (Coefficient of Variation)</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>CV (Coefficient of Variation)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Glycemic Variability (Standard Deviation)</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>SD (Standard Deviation)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>glycemic control variables HbA1C</measure>
    <time_frame>baseline and each visit(6weeks, 12weeks)</time_frame>
    <description>HbA1C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>glycemic control variables Fasting Plasma Glucose</measure>
    <time_frame>baseline and each visit(6weeks, 12weeks)</time_frame>
    <description>Fasting Plasma Glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lipid profile Total cholesterol</measure>
    <time_frame>baseline and each visit(6weeks, 12weeks)</time_frame>
    <description>Total cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lipid profile Triglyceride</measure>
    <time_frame>baseline and each visit(6weeks, 12weeks)</time_frame>
    <description>Triglyceride</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lipid profile HDL-cholesterol</measure>
    <time_frame>baseline and each visit(6weeks, 12weeks)</time_frame>
    <description>HDL-cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lipid profile LDL-cholesterol</measure>
    <time_frame>baseline and each visit(6weeks, 12weeks)</time_frame>
    <description>LDL-cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>glycemic control variables Percentage of patients achieving HbA1c &lt; 7%</measure>
    <time_frame>12weeks</time_frame>
    <description>Percentage of patients achieving HbA1c &lt; 7%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>glycemic control variables Percentage of patients achieving HbA1c &lt; 6.5%</measure>
    <time_frame>12weeks</time_frame>
    <description>Percentage of patients achieving HbA1c &lt; 6.5%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>glycemic control variables 24hr urinary glucose excretion</measure>
    <time_frame>baseline and 12weeks</time_frame>
    <description>24hr urinary glucose excretion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>glycemic control variables Changes in insulin dose</measure>
    <time_frame>baseline and each visit(6weeks, 12weeks)</time_frame>
    <description>Changes in insulin dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood pressure SBP</measure>
    <time_frame>baseline and each visit(6weeks, 12weeks)</time_frame>
    <description>SBP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood pressure DBP</measure>
    <time_frame>baseline and each visit(6weeks, 12weeks)</time_frame>
    <description>DBP</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">86</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>dapagliflozin 10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>a group which treated with dapagliflozin 10mg plus basal insulin therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo 10mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>a group which treated with dapagliflozin placebo plus basal insulin therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin</intervention_name>
    <arm_group_label>dapagliflozin 10mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>placebo 10mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female and male aged 20~70 years&#xD;
&#xD;
          2. Type 2 diabetes patients&#xD;
&#xD;
          3. Treatment on basal insulin therapy ≥0.2U/kg/day(±metformin and/or ±sulfonylurea) for&#xD;
             at least 12 weeks&#xD;
&#xD;
          4. Inadequate glycemic control ; HbA1c 7.0%~10.0% at screening&#xD;
&#xD;
          5. Female of childbearing potential agrees to routinely use of adequate contraception&#xD;
             from signing of the informed consent throughout the duration of the study&#xD;
&#xD;
          6. Understands the study procedure, alternatives, and risks and voluntarily agrees to&#xD;
             participated by giving written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Type 1 diabetes(Fasting C-peptide ≤ 0.78ng/dL(or 0.26 nM/L)), secondary diabetes,&#xD;
             gestational diabetes&#xD;
&#xD;
          2. Insulin therapy modalities containing short or rapid acting insulin (continuous&#xD;
             subcutaneous insulin injection, pre-mixed insulin, basal-bolus insulin)&#xD;
&#xD;
          3. History of diabetic ketoacidosis, hyperglycemic hyperosmolar state&#xD;
&#xD;
          4. Estimated glomerular filtration rate &lt;60 mL/min/1.73 m2&#xD;
&#xD;
          5. History of chronic cystitis or recurrent urinary tract infection&#xD;
&#xD;
          6. Currently on loop diuretics&#xD;
&#xD;
          7. Adrenal insufficiency, pituitary insufficiency&#xD;
&#xD;
          8. Currently on medication known to affect glucose metabolism (e.g. corticosteroids,&#xD;
             immunosuppressants)&#xD;
&#xD;
          9. Hemoglobin &lt;10g/dL in female, &lt;12g/dL in male&#xD;
&#xD;
         10. Abnormal liver function (AST/ALT &gt; x3 upper normal limit)&#xD;
&#xD;
         11. On weight loss program or taking weight loss medication&#xD;
&#xD;
         12. NYHA class III, IV congestive heart failure&#xD;
&#xD;
         13. History of acute myocardial infarction, unstable angina, coronary artery bypass graft&#xD;
             or stroke within 6 months&#xD;
&#xD;
         14. History of bladder cancer&#xD;
&#xD;
         15. History of malignancy within 5 years&#xD;
&#xD;
         16. Pregnant or lactating women&#xD;
&#xD;
         17. History of excessive alcohol abuse (≥30g/day)&#xD;
&#xD;
         18. Hypersensitivity to SGLT2 inhibitors&#xD;
&#xD;
         19. Patient with rare hereditary problems of galactose intolerance, the Lapp lactase&#xD;
             deficiency or glucose-galactose malabsorption.&#xD;
&#xD;
         20. Subject who the investigator deems inappropriate to participate in this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kun-Ho Yoon, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul St. Mary's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul St.Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>May 26, 2015</study_first_submitted>
  <study_first_submitted_qc>June 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2015</study_first_posted>
  <last_update_submitted>July 12, 2017</last_update_submitted>
  <last_update_submitted_qc>July 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Catholic University of Korea</investigator_affiliation>
    <investigator_full_name>Kun-Ho Yoon</investigator_full_name>
    <investigator_title>Professor of endocrinology division, Department of Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>dapagliflozin</keyword>
  <keyword>glucose variability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dapagliflozin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

